FDA Warns of Serious Liver Injury Risk with AbbVie's (ABBV) Viekira Pak

FDA warns of serious liver injury risk with Viekira Pak, according to Bloomberg headlines. The FDA will require Abbvie (NYSE: ABBV) to add new safety risk to its labels.

UPDATE - The FDA issued the following safety announcement on Thursday:

The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.

Read more....

Labels: ,